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(57) ABSTRACT 
Spin trapping compositions in general have now been dis 
covered to be effective in treating a variety of disorders, 
including disorders such as those arising from ischemia, 
infection, in?ammation, exposure to radiation or cytotoxic 
compounds, not just of the central and peripheral nervous 
systems but of peripheral organ disease having a wide 
variety of etiologies. In the preferred embodiment, the 
compositions for treating tissue damage from ischemia 
contain PBN, or active derivatives thereof, in a suitable 
pharmaceutical carrier for intravenous, oral, topical, or 
nasal/pulmonary administration. Other preferred spin 
trapping agents include 5,5-dimethyl pyrroline N-oxide 
(DMPO), ot-(4-pyridyl-1-oxide)-N-tert-butylnitrone 
(POBN), and (TEMPO) and spin-trapping derivatives 
thereof. Examples of derivatives of PBN include haloge 
nated derivatives, bifunctional derivatives, conjugates with 
drugs or targeting molecules, dimers and cyclodextran poly 
mers of PBN. Many different disorders can be treated using 
these compounds, including diseases or disorders of the 
central and peripheral nervous systems, and disorders aris 
ing from ischemia, infection, in?ammation, oxidation from 
exposure to radiation or cytotoxic compounds, as well as due 
to naturally occurring processes such as aging. 
20 Claims, No Drawings 
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SPIN TRAPPING PHARMACEUTICAL 
COMPOSITIONS AND METHODS FOR USE 
THEREOF 
This application is a continuation of Ser. No. 08/969, 
344, ?led on Nov. 28,1997 now US. Pat. No. 6,002,001, 
Which is a continuation of Ser. No. 08/167,900, ?led Jul. 29, 
1994, abandoned on Dec. 2, 1997, Which is a continuation 
in-part of Ser. No. 08/212,800, ?led Mar. 15, 1994, now US. 
Pat. No. 5,622,994, Which is a continuation of Ser. No. 
08/052,870, ?led Apr. 23, 1993, abandoned on Mar. 22, 
1994, Which is a continuation of Ser. No. 07/716,952, ?led 
Jun. 18, 1991, abandoned on Apr. 26, 1993. 
BACKGROUND OF THE INVENTION 
The present invention is a method and compositions 
containing spin trapping agents for the treatment of dys 
functions and disease conditions arising from oxidative 
damage. 
Oxygenated tissue suffers damage, in many cases perma 
nent damage, if it becomes ischemic and is then reperfused. 
Brain appears to be highly susceptible to ischemia/ 
reperfusion injury. Certain areas of the brain, for example, 
the hippocampus and spinal cord, are more susceptible than 
other regions of the brain. As a result, ischemia/reperfusion 
injury to brain may have a multiplicative effect simply 
because of the necessity for complete integrity of all regions 
in order to have proper functioning. 
Free radicals have been postulated to be mediators of 
reperfusion damage. The most likely sites for production of 
such radicals as the superoxide (O_2) and hydroxyl (OH—) 
species, and the precursor oxygen species, H2O2 are the 
mitochondrial respiratory chain speci?c enZymes and the 
sequences catalyZed by cyclooxygenase and lipoxygenase. 
HoWever, radicals are also formed during autoxidation of 
many compounds (e.g., catecholamines). Ischemia appears 
to favor a spurt of free-radical formation, resulting in 
oxidation of polyenoic free fatty acids, release and reuptake 
of catecholamines, and oxidation of hypoxanthine by xan 
thine oxidase. Despite these events occurring during 
recirculation, When the O2 supply is restored, they represent 
metabolic cascades triggered by agonist-receptor 
interactions, energy failure, and/or calcium in?ux during the 
insult. 
Although free radical formation has been postulated to be 
a likely cause of ischemic damage, it Was dif?cult to directly 
demonstrate that such formation occurs and/or that it Was 
suf?ciently pronounced to overWhelm the antioxidative 
defense of the tissue, as revieWed by Curran, et al., Mol. 
Cell. Biol. 5, 167—172 (1985). Phenyl butyl nitrone (PBN) 
has been used in a number of these in vitro research studies 
using spin trapping to look for free radicals, but until 
demonstrated by the data in US. Ser. No. 07/422,651, now 
US. Pat. No. 5,025,032, there has been no data to support 
the proposition that it could be useful in vivo, particularly 
With respect to treatment of tissue damage in the central 
nervous system. In vivo, the drug must be able to both cross 
the blood brain barrier and act in a manner Which reduces 
tissue damage during or folloWing ischemia. 
In US. Ser. No. 07/589,177, abandoned on Mar. 5, 1993, 
the use of PBN and related compounds, as Well as 5,5 
dimethyl pyrroline N-oxide (DMPO) and ot-(4-pyridinyl-1 
oxide)-N-tert-butylnitrone (POBN), for treatment of aging 
Was described. Age related changes in central nervous 
system function have generally been associated With the loss 
of cells, a Widening of lateral ventricles and de?cits in short 
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2 
term memory. The precise mechanisms of functional 
changes as a result of aging, or other diseases associated 
With aging, have not generally been agreed upon, including 
several mechanisms for the generation of oxidiZed material 
in the brain. A marked reduction in certain neurotransmitter 
receptor systems has been associated With increased oxida 
tion of proteins. For example, decreases in muscarinic 
receptors and other cholinergic systems have been charac 
teriZed as they relate to alterations in functions in AlZhe 
imers disease. It is noW knoWn that the processes of aging 
and AlZheimer’s disease are associated With oxidation of 
brain proteins. It has also been hypothesiZed that aging is 
associated With multiple minor periods of ischemia (multi 
infarct conditions or transient ischemia attacks) Which, over 
a period of time, may give rise to the production of oxidiZed 
protein. 
The demonstration in a variety of systems, both neural 
and nonneural, that there is an age related enhancement of 
the level of oxidiZed protein in tissue gives rise to the 
possibility that age related dysfunctions in the central ner 
vous system may be associated With the build-up of oxidiZed 
proteins and oxidiZed macromolecules Within neurons 
throughout the central nervous system. The hypothesis is 
that cells Which have a buildup of oxidiZed protein are less 
functional and less able to maintain the speci?ed role of 
those cells in that particular area of the central nervous 
system. The data presented in US. Ser. No. 07/589,177 
abandoned on Mar. 5, 1993, Was the ?rst report of substan 
tial investigations in Which alterations in the oxidiZed pro 
tein burden of the central nervous system Was manipulated 
and correlated With a functional outcome on the part of the 
animal. There are a number of other disorders and diseases 
Which have noW been postulated to be associated With 
oxidation of proteins, including many central nervous sys 
tem (CNS) diseases besides stroke and aging, including 
Parkinsonism, trauma, vascular headaches, cerebral palsy, 
diabetic neuropathy,and neuroanesthesia adjunct, as Well as 
peripheral nervous system diseases such as diabetic periph 
eral neuropathy and traumatic nerve damage, as Well as 
peripheral organ diseases. Examples of peripheral organ 
diseases include atherosclerosis, pulmonary ?brosis, 
pancreatitis, angioplasty, multiple organ failure, burns, decu 
bitus ulcers, and ischemic boWel disease. 
It is therefore an object of the present invention to provide 
spin-trapping compositions and methods for use thereof 
Which are useful in preventing or reversing ischemic damage 
in vivo, in the CNS, resulting from diseases such as stroke, 
aging, Parkinsonism, concussion, Berry aneurysm, ventricu 
lar hemorrhage and associated vasospasm, spinal cord 
trauma, vascular headaches, and neuroanesthesia adjunct. 
It is another object of the present invention to provide 
spin-trapping compositions, and methods for use thereof, 
Which are useful in treating damage in vivo resulting from 
peripheral nervous system diseases, including diabetic 
peripheral neuropathy and traumatic nerve damage. 
It is still another object of the present invention to provide 
spin-trapping compositions, and methods for use thereof, 
Which are useful in preventing or reversing free radical 
damage in vivo resulting from injury, infection and 
in?ammation, especially peripheral organ diseases such as 
chronic obstructive pulmonary disease (COPD), atheroscle 
rosis (both diabetic and spontaneous), pulmonary ?brosis 
due to anti-cancer treatment, drug treatment, pancreatitis, 
angioplasty, multi-organ failure folloWing trauma, burns 
(chemical, thermal, and radiation), the progressive loss of 
myocardial cells leading to cardiac failure as a result of 
age-related oxidation, and ischemic boWel disease. 
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It is another object of the present invention to provide 
spin-trapping compositions for use in the process of organ 
transplantation and preservation. 
It is a further object of the present invention to treat 
disorders not associated With oxidation, such as undesirable 
HDL/LDL ratios, as Well as the treatment of damage arising 
from exposure to cytotoxic compounds and radiation. 
SUMMARY OF THE INVENTION 
Spin trapping compounds in general have noW been 
discovered to be effective in treating a variety of disorders, 
including disorders such as those arising from ischemia, 
infection, in?ammation, exposure to radiation or cytotoxic 
compounds, not just of the central and peripheral nervous 
systems but of peripheral organ disease having a Wide 
variety of etiologies. 
Spin trapping compounds as referred to herein are mol 
ecules that (1) have an unpaired electron; (2) form a stable 
compound or complex With a free radical; and (3) are 
nontoxic, i.e., have a therapeutic index (margin of safety; 
ECSO/LCSO) of 3 or more. 
The spin traps provide a unique signal that can be mea 
sured by electron spin spectroscopy (ESR) When it binds to 
a free radical. For example, the oxidation of brain tissue 
involves a free radical intermediate. Brain tissue that has 
been treated With PBN has been monitored by ESR. As a free 
radical on a lipid or protein is generated, PBN traps the 
radical and forms a covalently bound product With the 
material, Which has a characteristically unique ESR signal. 
The PBN-(lipid or protein) has then been isolated and 
identi?ed. 
AWide range of spin trapping compounds are disclosed in 
detail herein. Other spin traps that meet the above three 
requirements are knoWn to those of skill in the art of organic 
and medicinal chemistry. An essential criteria for the selec 
tion of the spin trap is that it actively trap free radicals 
Without cytotoxicity, and that in the applications Where 
access to the CNS is required for efficacy, that the com 
pounds pass through the blood brain barrier. 
Many different disorders can be treated using these 
compounds, including diseases or disorders of the central 
and peripheral nervous systems, and disorders arising from 
ischemia, infection, in?ammation, oxidation from exposure 
to radiation or cytotoxic compounds, as Well as due to 
naturally occurring processes such as aging. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The term alkyl, as used herein, unless otherWise speci?ed, 
refers to a saturated straight, branched, or cyclic hydrocar 
bon of C1 to C10, and speci?cally includes methyl, ethyl, 
propyl, isopropyl, cyclopropyl, butyl, isobutyl, t-butyl, 
pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, 
cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3 
dimethylbutyl, and cyclohexyl. 
The term alkenyl, as referred to herein, and unless oth 
erWise speci?ed, refers to a straight, branched, or cyclic (in 
the case of C5_6) hydrocarbon of C2 to C10 With at least one 
double bond. 
The term aryl, as used herein, and unless otherWise 
speci?ed, refers to phenyl or substituted phenyl, Wherein the 
substituent is halo or loWer alkyl. 
The term halo, as used herein, includes ?uoro, chloro, 
bromo, and iodo. 
The term aralkyl refers to an aryl group With an alkyl 
substituent. 
1O 
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The term alkaryl refers to an alkyl group that has an aryl 
substituent. 
The term halo (alkyl or alkenyl) refers to an alkyl or 
alkenyl group in Which at least one of the hydrogens in the 
group has been replaced With a halogen atom. The term 
haloalkyl speci?cally includes tri?uoromethyl. 
The term aralkyl refers to an aryl group With an alkyl 
substituent. 
The term pharmaceutically active derivative refers to any 
compound that upon administration to the recipient, is 
capable of providing directly or indirectly, the compounds 
disclosed herein. 
The term alkaryl refers to an alkyl group that has an aryl 
substituent. 
The term nontoxic refers to a compound that has a 
therapeutic index of at least three. 
The invention disclosed herein includes pharmaceutical 
compositions that contain spin trapping compounds or phar 
maceutically acceptable derivatives or salts thereof for use 
in medical therapy, for example for the treatment or pro 
phylaxis of disorders such as those arising from ischemia, 
infection, in?ammation, exposure to radiation or cytotoxic 
compounds, not just of the central and peripheral nervous 
systems but of peripheral organ disease having a Wide 
variety of etiologies. 
The invention also includes the use of spin trapping 
agents and pharmaceutically acceptable derivatives or salts 
thereof in the manufacture of a medicament for treatment or 
prophylaxis of disorders such as those arising from 
ischemia, infection, in?ammation, exposure to radiation or 
cytotoxic compounds, not just of the central and peripheral 
nervous systems but of peripheral organ disease having a 
Wide variety of etiologies. 
It has noW been discovered that spin-trapping agents are 
generally useful in preventing or treating symptoms associ 
ated With a very Wide range of disorders of the central and 
peripheral nervous system, as Well as peripheral organ 
disfunction and disease, including not just aging, trauma, 
ischemia but disorders as disparate as undesirable ratios of 
lipoproteins, ulcerative colitis, and damage arising from 
exposure to radiation and cytotoxic compounds 
(chemotherapeutic compounds, in most instances). 
Useful Spin-trapping Compounds. 
PBN and derivatives thereof. 
The preferred spin-trapping compounds are phenyl 
N-tert-butylnitrone, also referred to as ot-phenyl t-butyl 
nitrone (PBN), and derivatives thereof of the formula: 
Wherein: 
X is phenyl, imidaZolyl, phenothiaZinyl or 
R2 
3“ 
n=1—5, preferably 1—3; 
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-continued 
(I) CH3 CH3 
/ \ C=N C—N=N—C—CH3 
R3)!‘ | | H CH3 0 CH3 
T CH3 
/ \ C: + CH3 and 
WW I H CH3 
Se CH3 
wherein R3=independently R2 (that can vary Within the 
molecule) or H; 
and R4 to R9 are independently R2, H or 
/ \ 
_e.\R, 
Other spin-trapping agents can also be used, such as 
5,5-dimethyl pyrroline N-oXide (DMPO), ot-(4-pyridyl 
1-oXide)-N-tert-butylnitrone (POBN), 3,3,5,5-tetramethyl 
1 -pyrroline N-oXide, and 2,4,4,6-tri-tert 
butylnitrosobenZene (BNB), and spin-trapping derivatives 
thereof. Many compounds are commercially available or can 
be synthesiZed using methods knoWn to those skilled in the 
art. ot-phenyl-N-phenylnitrone compounds for use as topical 
antiin?ammatories are described by US. Pat. No. 4,224,340 
to Campbell, et al., the teachings of Which are incorporated 
herein. 
DMPO and Derivatives Thereof 
The general formula for DMPO, and speci?c derivatives 
are: 
A / 
N+ 
B | 
0 
wherein A and B are independently —R2, —CH2OH, 
—CH2OW, or 
_ R2 
m‘ _ 
n is an integer from 1 to 5; and 
Wis 
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8 
speci?cally including 
O 
H 
—CCH3, 
or —Z 
O 
H 
O—C 
CH3 
/ CH3 / 
CH 
3 T T 
O O 
DMPO dimer 
CH3 CH3 
O 
O—N O—l|:—C 
/ \N/ 
CH3 I 
CH3 CH3 0 
DMPO covalently bound to TEMPO 
PBN covalently bound to DMPO 
POBN and Derivatives Thereof. 
The general formula for POBN is: 
0. 
Wherein m = O to 4 
TEMPO and Derivatives Thereof. 
2,2,6,6-Tetramethyl piperidinooXy (TEMPO) is a nitroX 
ide organic free radical trap. The synthesis and chemistry of 
nitroXide free radicals is referenced by Galfnley, B. J ., pp. 
184—238 in Spin Labeling in Pharmacology Berliner, L. H., 
(Academic Press, NY, NY. 1976), the teachings of Which are 
incorporated herein. TEMPO and several derivatives thereof 
can be purchased from Aldrich Chemical Co., as can many 
other spin traps such as PBN, DMPO, and POBN and some 
of their derivatives. 
As discussed above, the important criteria for these com 
pounds is that they must trap free radicals, especially 
hydroXy and superoXide radicals, While remaining non-toXic 
to normal cells. In those applications Where the compound 
must reach the brain and other parts of the CNS, the 
compound must also be loW molecular Weight to pass 
through the blood brain barrier. In some applications, the 
higher molecular Weight dimers and polymers of the spin 
trap may have advantages. 
Conjugates and Polymers of Spin Trapping Compounds. 
In another embodiment, spin trapping compounds are 
covalently attached to knoWn pharmaceutical agents, by 
methods knoWn to those skilled in the art. Examples of 
US 6,403,627 B1 
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useful compounds include spin traps covalently bound to 
antiin?ammatories, neuroactive compounds, antioxidants, 
or calcium channel blockers. Examples as illustrated include 
conjugates of acetaminophen, dopamine (or DOPA), vitamin 
E, and nifediphene. 
T 
CH3—C—I|\I OH ACETAMINOPHEN 
H 
T T CH3 
:N CH3 
O H 
II | CH3 
CH3—C—N o 
O C 
/ \ | | | || | 
C=N—C—CH2—C—N OH 
3»8“_ l 
R CH3 
NO; 
I l NIFEDIPHENYL PBN 
MeOC N COMe 
H—C 
|| 
T—O 
CH3—C—CH3 
CH3 
T T T T CH3 
CH3—C—N o C=N CH3 
CH3 
HO CH2—CH2—NH2 DOPAMINE 
HO 
PII O 
HO CH2—C—C—OH DOPA 
NH2 
HO 
Derivatives of DOPA 
— T T CH3 
\ CH2—C=N CH3 
3%“ / R CH3 
20 
25 
35 
45 
55 
Other drugs that can be covalently bound to the spin traps 
include calcium channel blockers such as nimodipine, 
nicardipine, nifedipine, nitrendipine, diltriaZam and ?una 
raZine; cardiac glycosides such as digitalis and analogues 
thereof; adenergic antagonists such as propranalol; metal 
chelators such as desferal; modi?ed steroids such as laZ 
aroids; antiin?ammatories such as prednisone; nonsteroidal 
antiin?ammatories such as acetaminophen, ibuprofen, and 
indomethacin; antioxidants such as vitamin E; and neuro 
active compounds such as L-DOPA. The optimal position to 
bind the spin trap to the pharmaceutical agent is easily 
determined using knoWn information on structure activity 
relationships and bulk tolerance of the pharmaceutical agent. 
In some cases spacers Will be required betWeen the spin-trap 
and the conjugated compound in order to preserve maximum 
activity. 
Spin traps can also be attached to antibodies or ligands for 
speci?c receptors (such as certain hormones, enZymes, or 
even speci?c sugars or carbohydrates) Which are used to 
“target” or otherWise concentrate the spin trapping com 
pound. Depending on the structure of the spin trap, as Well 
as the biologically active compound, it may be necessary to 
insert a spacer betWeen the spin trap and the biologically 
active compound. 
Indications that the compositions are useful in treating. 
The spin trap or free-radical scavenger compositions are 
useful in treating a variety of dysfunctions or disorders 
characteriZed by oxidiZed proteins or lipids in the tissues, 
cells, or associated ?uids (such as the blood). Oxidation of 
cytosolic protein has been demonstrated to occur in a Wide 
variety of pathological conditions. 
Accordingly, compounds Which have as their fundamental 
mechanism of action the interference of production of 
US 6,403,627 B1 
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oxidized protein are useful in the treatment of a Wide variety 
of diseases having What appears at ?rst glance to be Widely 
dissimilar etiologies, because the fundamental cause of the 
condition is oxidation of protein, nucleic acids, or lipids. 
Disorders are generally divided into disorders of the 
central and peripheral nervous’system and disorders of the 
peripheral organs. 
Disorders of the CNS include stroke, aging, 
Parkinsonism, concussion, aneurysm, ventricular hemor 
rhage and associated vasospasm, migraine and other vascu 
lar headaches, spinal cord trauma, diabetic retinopathy, and 
neuroanesthesia adjunct. Disorders of the peripheral nervous 
system include diabetic peripheral neuropathy and traumatic 
nerve damage. 
Peripheral organ disease includes atherosclerosis (both 
diabetic and spontaneous), chronic obstructive pulmonary 
disease (COPD), pancreatitis, pulmonary ?brosis due to 
chemotherapeutic agents, angioplasty, trauma, burns, 
ischemic boWel disease, Wounds, ulcers and bed sores, 
lupus, ulcerative colitis, organ transplantation, renal 
hypertension, overexertion of skeletal muscle, and epistaxis 
(pulmonary bleeding). 
Other conditions associated With excessive oxidation of 
proteins or lipids that can be treated include undesirable or 
altered oxidation of loW density lipoprotein, and dysfunction 
from exposure to radiation, including x-ray, ultraviolet, 
gamma and beta radiation, and cytotoxic compounds, 
including those used for chemotherapy for cancer and viral 
infections. 
Treatment of Central Nervous System Diseases 
Stroke 
Multiple in vitro studies, as Well as the in vivo data 
presented in US. Ser. No. 07/589,177 abandoned on Mar. 5, 
1993, and US. Ser. No. 07/422,651 now US. Pat. No. 
5,025,023, have demonstrated that there are a series of 
biochemical changes that result in the production of free 
radicals folloWing ischemia. PBN and other spin-trapping 
compounds can covalently bind to these radicals and prevent 
the peroxidation of cellular proteins and fatty acids. The 
consequence of the trapping of these carbon-centered and 
oxygen-centered radicals is the termination of the propaga 
tion phase of free radical production Within the neuron. This 
interruption of free radical production can decrease the 
mortality and morbidity seen in strokes. 
Aging 
Aging has been demonstrated to be associated With the 
production of abnormally high levels of oxidiZed proteins. 
The consequence of this increased level of protein oxidation 
is an abnormally loW level of critical enZymes in the affected 
cells. While not all cells have been evaluated, it appears 
from the in vivo data presented in US. Ser. No. 07/589, 
177abandoned on Mar. 5, 1993, and US. Ser. No. 07/422, 
651, now US. Pat. No. 5,025,032, and reports of in vitro 
studies, that most, if not all, cells in the body Will undergo 
abnormally high levels of protein oxidation. Decreases in 
antioxidant systems and abnormally loW levels of mitochon 
drial function have been described. The protein oxidation is 
thought to arise from oxygen free radicals, largely generated 
via a metal catalyZed reaction Within the cell. Studies have 
noW been conducted that daily administration of a free 
radical spin trapping compound, PBN, for fourteen days 
completely reverses this process. Not only is the level of 
protein oxidation decreased, but the abnormally loW level of 
enZyme activity is restored to normal. 
Parkinsonism 
Research has indicated that one of the principle sources of 
dopaminergic damage to the striatum is via free radical 
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12 
mediated oxidation. Dopamine can be oxidiZed to the neu 
rotoxin 6-OH dopamine Within the neuron. This neurotoxin 
is activated by a second oxidation. Both of these reactions 
are thought to occur as a result of oxygen free radical 
production and attack on the dopamine, a naturally occur 
ring neurotransmitter. These oxygen radical mediated oxi 
dations are thought to occur at a relatively sloW rate and to 
be responsible for the progressive loss of motor function in 
Parkinsonism and related conditions. Based upon the dem 
onstration that chronic administration of PBN can decrease 
the progressive oxidation that occurs folloWing a stroke, it is 
believed that PBN and other spin-trapping compounds Will 
be effective in limiting the production of the neurotoxic 
dopamine oxidation products. 
Concussion 
The majority of the research literature indicates that 
concussion produces the bulk of its long term effects via 
interruption of brain and spinal cord microcirculation, pro 
ducing localiZed ischemia. This interruption in blood flow 
can be the result of the initial trauma and shearing of 
capillaries or the consequence of the brain edema and 
compression of the blood vessels. In any event, spin trapping 
compounds are of therapeutic value as they have been 
demonstrated to be in models of stroke. 
Berry Aneurysm and other types of aneurysm 
This vascular problem results in bleeding on the brain and 
presents as a serious and chronic headache or other neuro 
logic symptom. The condition is ultimately treated by sur 
gical repair of the vessel that has developed a Weak Wall. 
HoWever, this condition often results in hemorrhage and 
neural damage due to the bleeding. In addition, the presence 
of blood on the outside of the vessel sensitiZes the vessels to 
spasm and increases the risk of a stroke, as is also true in 
concussion and other traumatic conditions. In addition to the 
radicals generated by spasm and stroke, the iron or other 
metal catalyZed generation of oxygen free radicals, similar 
to What has been proposed for ischemia and concussion, also 
represents a second source of free radicals. 
Ventricular Hemorrhage and Associated Vasospasm 
The same biochemical and physiological conditions as 
described for Berry Aneurysm and their management by 
spin trapping compounds Will apply for these conditions. 
Migraine and other Vascular Headaches 
Migraines are thought to arise in part from large vessel 
vasodilation and compression of the microcirculation of the 
cortex. This is another form of ischemia/reperfusion injury. 
While spin-trapping compounds Will not prevent the initial 
occurrence of these vascular headaches, they limit the extent 
or frequency by trapping the free radicals that are generated 
during the ischemia phase. 
Spinal Cord Trauma 
Spinal cord trauma involves the interruption of the normal 
vascular supply due to shearing forces at the time of the 
initial trauma and as a result of the subsequent edema of the 
tissue. In addition, the hemorrhage that often accompanies 
such trauma Will also generate vasospasm and directly 
generated oxygen free radicals. Spin trapping compounds 
limit this process and terminate the intracellular cascade of 
lipid and protein oxidation. 
Neuroanesthesia Adjunct 
Several procedures involve resection of brain tissue Which 
Will result in hemorrhage in the immediate area. Other 
surgical procedures may be associated With increased risk of 
cerebral blood flow interruption, either as a natural conse 
quence of the procedure, e.g., cardiac surgery or heart 
transplantation, or due to the unexpected interruption of 
110W, e.g., hemorrhage, clot folloWing angioplasty, cardiac 
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arrest during surgery. In all of these conditions, spin 
trapping compounds Will limit free radical mediated 
damage, and Will limit the development of antigenic reac 
tions or other changes in the vascular endothelium that Will 
increase the risk of the development of a reaclusive injury. 
Reduction in free radical mediated damage limits antigen/ 
antibody mediated tissue damage. 
Peripheral Nervous System Diseases 
Diabetics are Well knoWn for their tendencies to develop 
peripheral neuropathies and progressively lose sensation in 
limbs. In addition, diabetics have a higher risk to develop 
atherosclerosis, Which may affect microvascular function. 
One of the most frequently seen biochemical consequences 
of diabetes is excessive glycation of proteins. It is believed 
that folloWing glycation, there is a burst of protein oxidation 
that is mediated by oxygen free radicals. It is thought that 
this process of excessive glycation is critical in the devel 
opment of damage to neurons and axons in the diabetic. 
Since spin trapping compounds are quite effective in limit 
ing intracellular free radical mediated damage, such com 
pounds can be used in the chronic management of diabetic 
neuropathies and other long term adverse consequences of 
diabetes. 
Traumatic Nerve Damage 
Crushing injury to peripheral nerves, as in the hands, 
arms, and legs, involves interruption of blood ?oW 
(ischemia) and edema. Effective and prompt repair is depen 
dent on the re-establishment of an effective oxygen and 
nutrient supply. Often recovering tissue tends to outgroW its 
blood supply and is restricted in recovery by the ischemia 
that occurs as the tissue outgroWs the vascular supply. 
Spin-trapping compounds can be used to provide greater 
tolerance of partial hypoxia as vascular supply groWs to 
reach the healing tissue. In addition, the same ischemia/ 
hypoxia protection that occurs in the non-vascular tissue 
may also enhance the groWth of the endothelia as the 
revasculariZation process occurs. 
Peripheral Organ Diseases 
Atherosclerosis (both diabetic and spontaneous 
Diabetic atherosclerosis involves the abnormal and exces 
sive glycation of protein in the vascular Wall. As discussed 
above for diabetic neuropathy, this involves oxygen radical 
production and consequent further damage to cytosolic 
proteins. Spin-trapping compounds Will prevent this abnor 
mal processing of cellular protein and other cellular con 
stituents. In vitro studies have been conducted that demon 
strate that PBN inhibits or reduces oxidation of loW density 
lipoprotein in plasma. Plasma samples Were tested for oxi 
dation of lipid measured using thiobarbioturic acid reactive 
substance (TBAR, nM) and % inhibition of oxidation calcu 
lated. Phosphate buffered saline (PBS) Was added to 
controls, 0.1 mM PBN Was added to test samples, and the 
controls and sealed samples incubated at 4° C. for seven 
Weeks. 
The results are shoWn in Table 1. 
TABLE 1 
Testing of antioxidation activity of PBN 
control + Test 
sample PBS (nM/ml) % inhibition" 
NP132 plasma 0.55 0.45 18.2 
NP134 plasma 0.18 0.14 22.2 
NP135 plasma 0.32 0.25 21.9 
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TABLE 1-continued 
Testing of antioxidation activity of PBN 
control + Test 
sample PBS (nM/ml) % inhibition" 
NP133 LDL 0.54 0.28 48.1 
NP135 LDL 0.33 0.11 66.7 
*The actual percent inhibition in the presence of PBN is greater than the 
measured value due to interference in the assay by the PBN. 
Chronic Obstructive Pulmonary Disease (COPD) 
COPD has been demonstrated to involve the attack of 
interstitial alveolar macrophages on pulmonary tissue. Ani 
mal models of this clinical condition have demonstrated that 
increases or decreases in superoxide dismutase activity in 
the lung can result in decreases or increases in pulmonary 
pathology, respectively. An alternative approach is to pro 
vide to the pulmonary tissue, either via the pulmonary 
vascular supply or via the airWay, radical spin-trapping 
compounds Which Will limit the peroxidation of pulmonary 
tissue and the consequent loss of alveolar tissue. 
Pancreatitis 
Pancreatitis is believed to be the result of ischemic or 
chemically derived peroxidation of pancreatic parenchyma. 
Alcoholic pancreatitis is probably due to the direct effects of 
the ethanol radical and the indirect vascular effects of 
acetaldehyde mediated direct damage to proteins and indi 
rect damage via catecholamine release and mitochondrial 
metabolism. There is currently no treatment for acute pan 
creatitis. If the condition does not abate, it is generally 
regarded as fatal in the severe form. Spin-trapping agents 
can be used to mediate the acute reaction, alloWing the 
patient time to recover. 
Angioplasty 
In the process of re-expanding or laser removal of 
atheroma, there are periods of ischemia and reperfusion of 
the vessel or energy mediated production of free radicals. 
Recent studies have demonstrated that during this period, 
superoxide and nitric oxide are produced. These products 
have been demonstrated to further damage the endothelium 
and may also remove or damage the natural relaxant systems 
that locally control the vascular tone. If uncontrolled, such 
changes are likely to result in an increased risk of 
re-occlusion of the same vessel. Spin-trapping compounds 
can prevent the generation of the oxy-radical cascade and 
thereby reduce the likelihood of reocclusion folloWing 
angioplasty. In the diabetic, there is also an increased risk of 
cutaneous alteration associated With vascular dysfunction 
and poor perfusion of the dermis. 
Multi-organ failure folloWing trauma 
A characteristic problem folloWing extreme trauma is the 
development in the patient of a negative nitrogen balance, 
poor protein synthetic capacity, pulmonary dysfunction, and 
abnormal cytokine production. Tumor necrosis factor (TNF) 
is excessively elevated during this process. TNF is associ 
ated With the cellular generation of oxygen free radicals in 
tissue and may be one of the primary causes of this condi 
tion. The activation of macrophages and lymphocytes also 
plays a critical role in the condition. Free radical production 
by the White cells is part of the process of multiple organ 
damage. Spin-trapping compounds can prevent the propa 
gation phase of this condition and limit the extent of 
cachexia and organ damage folloWing severe trauma. 
Diabetic Retinopathy 
Diabetes is a disease of abnormal glycation and partial 
ischemia. Both conditions promote free radical production. 
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The relatively common condition of diabetic retinopathy is 
thought to involve a microvascular and protein dysfunction 
of the retina. Spin-trapping compounds can limit the glyca 
tion mediated production of free radicals and the damage 
caused by microvascular interruptions. 
Burn Treatment and Healing 
Healing from serious burns is limited by the inability of 
the repairing vascular system to supply the rapidly groWing 
cutaneum. Periods of ischemia in the dermis Will occur as 
the groWing skin cannot be adequately supplied. This 
hypoxia or ischemia results in the production of oxygen free 
radicals and either limits the rate of recovery and/or pro 
motes the generation of scar tissue. Systemic and topical 
spin-trapping compounds can be used to improve the rate of 
healing and decrease scar formation. 
Ischemic BoWel Disease 
Strangulation of the boWel is a condition that is frequently 
fatal in both humans and animals such as dogs, horses and 
cattle. Even after resection and anastomosis of the intestine, 
the prognosis is not good. The generation of ischemia 
derived oxygen radicals and damage to the intestine is 
considered to be a primary cause. There is no effective 
treatment to date. 
Studies have demonstrated that ischemia induced intesti 
nal edema can be prevented or reduced by a number of 
different spin-trapping compounds. 
Endotoxin is a primary factor in the pathophysiology of 
equine gastrointestinal disorders and gram negative bacterial 
infections. The pathophysiological is similar to that charac 
teriZing colitis, salmonellosis, and neonatal septicemia. It is 
hypothesiZed that endotoxin produces its toxic effects by 
triggering “oxidative bursts” from sensitiZed macrophages. 
These bursts of O2 radicals are intended to kill invading 
bacteria associated With the presence of endotoxin. 
HoWever, they have the adverse effect of damaging the 
tissues in Which they are produced and this tissue damage is 
presumably the molecular basis of the pathological changes 
associated With endotoxin shock. Spin-trapping compounds 
have the ability to trap radicals and alleviate many of the 
toxic effects associated With radical formation. Additionally, 
recent experiments demonstrate that spin trap molecules 
protect rats against endotoxin administration. 
Wound and Ulcer Healing 
Tissue healing often involves periods of hypoxia or 
ischemia as the recovering tissue outgroWs the vascular 
supply. Spin-trapping compounds can decrease the damage 
associated With this period of ischemia. 
Infections as consequence of the development of decubi 
tus ulcers is the number one cause of death in the elderly. 
The general clinical impression is that elderly patients are 
much more likely to develop these ulcers, compared to 
young adults. Pressure sores develop as a result of the 
interruption of blood How to the skin. This process is 
identical to the process of ischemia/reperfusion oxidation of 
brain and other tissues. In the geriatric and/or diabetic 
patient, pressure sores may develop due to enhanced oxida 
tion of the cells of the skin. Based upon the observations that 
spin-trapping compounds can prevent ischemia/reperfusion 
injury to both brain and intestine, it is expected that spin 
trapping compounds Will reduce or prevent pressure sores. 
In addition, these compounds can be used systemically or 
topically in enhancing recovery. 
Reduction in Side-effects of Cancer Chemotherapy 
A number of cancer chemotherapeutic agents produce 
their cytotoxic effects via the production of oxygen free 
radicals Within the cell. The limiting side effects of these 
compounds are also the result of oxygen free radical pro 
10 
15 
25 
35 
45 
55 
65 
16 
duction in normal cells. Bleomycin produces pulmonary and 
cutaneous toxicities as a result of hydroxyl free radical 
production. Adriamycin produces cardiac and gastrointesti 
nal side-effects. The spin-trapping compound PBN has been 
demonstrated to trap the free radicals produced by adriamy 
cin in heart, brain and other organs of research animals, 
using the spin-trapping compound PBN. These spin 
trapping compounds can be used to limit side effects in 
tissues, such as the brain and heart, that are especially 
vulnerable to develop free radicals, Without compromising 
the therapeutic value of the chemotherapeutic agent. 
Skin, Muscle Flap and Organ Survival FolloWing Trans 
plantation 
Autologous (self) transplantation of skeletal muscles from 
one area to another should not involve any immunologic 
incompatibilities. HoWever, estimates from one surgeon 
suggest that the success rate is more in the area of 50% 
success. Acceptance of skin ?ap grafts has an equally loW 
success rate. It is postulated that much of the problem arises 
as a result of ischemia and reperfusion during the surgical 
procedures for removal and implantation. FolloWing 
ischemia these tissues undergo calcium loading and even 
tually necrosis, as in strokes. Spin-trapping compounds can 
be used to limit the damage undergone by these tissues, as 
Well as other organs, during surgery associated With trans 
plantation. 
Organs for transplantation are obtained from donors. The 
success of the procedure is determined in part by the age 
(oxidation) related reduction in organ viability, the amount 
of time the organ is in preservation solution, and the status 
of the recipient. Previous research has demonstrated that 
spin-trapping compounds can improve the enZymatic status 
of the aged brain, restoring enZymatic levels to near those of 
the young adult as early as seven days folloWing initiation of 
daily treatment With a spin-trapping agent such as PBN. 
Organ preservation solutions are designed to prepare the 
organ to be transplanted for the period of extracorporeal 
storage. The most recently developed solution contains 
glutathione as an antioxidant. Spin-trapping compounds 
differ from glutathione in that they can function both as 
antioxidants, trapping oxygen free radicals, as Well as trap 
ping compounds for both intracellular and extracellular 
carbon-centered free radicals. 
It is believed organ survival Would therefore be enhanced 
by administering spin-trapping compounds to the recipient, 
as Well as adding the compounds to the organ preservation 
solution. 
IoniZing Radiation Prophylaxis. 
IoniZing radiation as a therapeutic modality and as an 
environmental toxicant causes its effects by producing 
hydroxyl free radicals intracellularly and extracellularly. 
Ultraviolet radiation acts similarly. The cascade that folloWs 
is functionally identical to the process of cellular damage 
caused by ischemia/reperfusion injury to tissue. Spin 
trapping compounds can be used to selectively treat those 
tissues that are not involved by the cancer, thereby increas 
ing the effectiveness of the therapy and decreasing the side 
effects of radiation therapies. In the case of environmental 
exposures, spin-trapping compounds should be effective 
both as a prophylaxis, applied topically or systemically, as 
Well as a post-exposure therapeutic. 
Treatment of Renal Hypertension Disorders, Resulting from 
LoW Renal Artery FloW and High Renin 
Renal hypertension develops as a result of reduced blood 
How to the kidney. The juxtaglomerular apparatus (JGA) 
recogniZes this hypoperfusion and releases renin, Which 
results in an angiotensin II mediated increase in blood 
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pressure (hypertension). Hypoperfusion (hypoxia) is a con 
dition that is known to result in signi?cant oxygen free 
radical production, making it probable that oxygen free 
radicals are likely to be involved in the release of renin by 
the JGA, and therefore manageable at least in part through 
administration of spin-trapping compounds. 
Exertional Injury to Skeletal Muscle 
Sore muscles as a result of exercise are thought to be a 
consequence of free radical mediated peroxidation of skel 
etal muscle proteins and lipids. Since chronic treatment With 
spin-trapping compounds decreases cellular oxidations and 
protects enZymes from oxidative inactivation, daily treat 
ment can be used to improve the process of exercise con 
ditioning (especially in the horse). Moreover, aged skeletal 
muscle is likely to contain constituents, as do most other 
cells in the body. Since Work has demonstrated that chronic 
administration of the spin-trapping compound PBN can 
return cells to the status of a young adult, spin-trapping can 
be used to improve the functional status and exercise con 
dition of skeletal muscle in aged individuals. 
Epistaxis (Pulmonary Bleeding in Horses) and Laminitis 
Epistaxis (ES) and laminitis are both thought to involve 
ischemia/reperfusion injury to the alveolar basement mem 
brane and the lamina propria of the hoof, respectively. Since 
both of these conditions involve the process of reperfusion 
generation of free radicals, spin-trapping compounds can be 
used in the prevention, management of treatment of these 
conditions. 
Pharmaceutical Compositions 
The spin trapping compounds are administered topically, 
locally, or systemically, depending on the application. When 
administered systemically, the compound is preferably 
administered orally or intravenously, in an appropriate phar 
maceutical carrier such as saline or phosphate buffered 
saline (PBS) or in tablet form. For topical application, the 
compound is preferably administered in an ointment or 
cream base, or by means of a transdermal patch. The 
compound can also be administered by controlled delivery 
devices, such as biodegradable polymers, or by inhalation, 
insuf?ation or nasal spray. Suitable carriers are knoWn to 
those skilled in the pharmaceutical area. 
Effective dosages of Spin Trapping Compounds 
A typical dose of the spin trapping agent for all of the 
above-mentioned conditions is in the range from about 0.1 
to 100 mg/kg, preferably 0.5 to 50 mg/kg, of body Weight 
per day. The effective dosage range of the pharmaceutically 
acceptable derivatives can be calculated based on the Weight 
of the parent spin trapping compound to be delivered. If the 
derivative exhibits activity. in itself, the effective dosage can 
be estimated as above using the Weight of the derivative, or 
by other means knoWn to those skilled in the art. 
The compound is conveniently administered in any suit 
able unit dosage form, including but not limited to one 
containing 5 to 2000 mg, preferably 50 to 1500 mg of active 
ingredient per unit dosage form. A oral dosage of 50—1000 
mg is usually convenient. 
Ideally the active ingredient should be administered to 
achieve peak plasma concentrations of the active compound 
of from about 0.5 to 100 mM, preferably about 1 to 30 mM. 
The concentration of active compound in the drug com 
position Will depend on absorption, inactivation, and excre 
tion rates of the drug as Well as other factors knoWn to those 
of skill in the art. It is to be noted that dosage values Will also 
vary With the severity of the condition to be alleviated. It is 
to be further understood that for any particular subject, 
speci?c dosage regimens should be adjusted over time 
according to the individual need and the professional judg 
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ment of the person administering or supervising the admin 
istration of the compositions, and that the concentration 
ranges set forth herein are exemplary only and are not 
intended to limit the scope or practice of the claimed 
composition. The active ingredient may be administered at 
once, or may be divided into a number of smaller doses to 
be administered at varying intervals of time. 
Exemplary dosages of the parent phenyl t-butyl nitrone 
administered intravenously range from 0.1 to 10 mg/kg of 
body Weight in animals. The effective dosage of PBN in 
humans for treating age and ischemic related disorders is 
expected to be betWeen approximately 1 and 10 mg/70 kg 
body Weight. Toxicity tests have demonstrated that PBN is 
completely innocuous, With such loW toxicity that it Was not 
possible to determine an LDSO. It is possible to extrapolate 
from comparative tests using other spin trapping compounds 
What the effective dosage for these compounds Will be. 
Since the trapping of endogenous free radicals is speci?c 
for only those cells that have been exposed to the conditions 
that result in the. production of free radicals, the traps have 
little or no effect on normal cells. The bene?cial effects 
occur only in injured cells, and do not require the presence 
of speci?c receptors, speci?c enZymes, and/or speci?c cell 
types. 
Methods of Administration of PBN 
The spin trapping compound is preferably administered 
systemically, most preferably intravenously or orally, since 
these are the most rapid and efficient means for delivering 
the active compound to the site of free radical generation. 
The spin trapping compound may be administered at once, 
or may be divided into a number of smaller doses to be 
administered at varying intervals of time. Other methods of 
systemic administration can also be used, including inhala 
tion or insuf?ation, subcutaneous, intravenous, and intrap 
eritoneal administration. The spin trapping compound can 
also be administered topically, in an ointment, creme, or 
transdermal patch. 
The spin trapping composition can be provided in the 
form of a pharmaceutically acceptable salt. As used herein, 
the term pharmaceutically acceptable salts or complexes 
refers to salts or complexes of that retain the desired 
biological activity of the parent compound and exhibit 
minimal, if any, undesired toxicological effects. Nonlimiting 
examples of such salts are (a) acid addition salts formed With 
inorganic acids (for example, hydrochloric acid, hydrobro 
mic acid, sulfuric acid, phosphoric acid, nitric acid, and the 
like), and salts formed With organic acids such as acetic acid, 
oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic 
acid, benZoic acid, tannic acid, pamoic acid, alginic acid, 
polyglutamic acid, naphthalenesulfonic acids, naphthalene 
disulfonic acids, and polygalacturonic acid; (b) base addi 
tion salts formed With polyvalent metal cations such as Zinc, 
calcium, bismuth, barium, magnesium, aluminum, copper, 
cobalt, nickel, cadmium, sodium, potassium, and the like, or 
With an organic cation formed from N,N-dibenZylethylene 
diamine, ammonium, or ethylenediamine; or combinations 
of (a) and (b); e.g., a Zinc tannate salt or the like. 
A preferred mode of administration of the active com 
pound is in a form for oral delivery. Oral compositions Will 
generally include an inert diluent or an edible carrier. 
Preferred pharmaceutical carriers for intravenous adminis 
tration are saline or phosphate buffered saline at physiologi 
cal pH. Since some compounds are pH sensitive, stability of 
the compound in the carrier should be determined and the 
pH of the carrier adjusted appropriately, or the compound 
administered in combination With food, a buffering agent, or 
in an enteric coating. For oral delivery, the spin trapping 
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compound may be enclosed in capsules, compressed into 
tablets, microencapsulated, entrapped in liposomes, in solu 
tion or suspension,alone or in combination With a substrate 
immobilizing material such as starch or poorly absorbable 
salts such as immodium. Pharmaceutically compatible bind 
ing agents can be included as part of the composition. The 
tablets or capsules may contain, for example, any of the 
following ingredients, or compounds of a similar nature: a 
binder such as microcrystalline cellulose, gum tragacanth or 
gelatin; an excipient such as starch or lactose, a disintegrat 
ing agent such as alginic acid, Primogel©, or corn starch; a 
lubricant such as magnesium stearate or Sterotes; a glidant 
such as colloidal silicon dioxide; a sWeetening agent such as 
sucrose or saccharin; or a ?avoring agent such as 
peppermint, methyl salicylate, or orange ?avoring. When 
the dosage unit form is a capsule, it can contain, in addition 
to material of the above type, a liquid carrier. In addition, 
dosage unit forms can contain various other materials Which 
modify the physical form of the dosage unit, for example, 
coatings of sugar, shellac, or other enteric agents. 
Modi?cations and variations of the spin trapping compo 
sitions for the treatment of a variety of disorders associated 
With oxidation of proteins and/or lipids Will be obvious to 
those skilled in the art from the foregoing detailed descrip 
tion. Such modi?cations and variations are intended to come 
Within the scope of the appended claims. 
We claim: 
1. Amethod for the treatment of dysfunctions and disease 
conditions arising from oxidative damage comprising 
administering to a patient in need of such treatment an 
effective amount of a compound of the formula 
Wherein: 
X is imidaZolyl, phenothiaZinyl or 
R2 
R2=independently (can vary Within the molecule) 
halogen, alkyl, alkenyl, oxyalkenyl, NHZ, NHZ, NZ2, 
NO, 
—S(alkenyl), and haloalkyl; 
A=O or S; and 
Z is a C1 to C6 straight or branched alkyl or cyclic group; 
and 
Y is a tert-butyl group that can be hydroxylated or 
acetylated at one or more positions; phenyl or 
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With the proviso that 
(a) both X and Y do not simultaneously represent 
R2 
Wherein n is 1 to 5 and Wherein R2 is halogen, alkyl, 
NHZ, —S(alkyl), haloalkyl, or 
In 
Where Z is a C1_6 straight or branched chain alkyl; 
and 
(b) Where Y is phenyl, then X does not represent 
S 
Where n is 1 to 5 and Wherein R2 is halogen or alkyl. 
2. The method of claim 1 Wherein the disorder is of the 
central and peripheral nervous system and disorders of the 
peripheral organs. 
3. The method of claim 2 Wherein the disorder is a 
disorder of a peripheral organ. 
4. The method of claim 3 Wherein said peripheral organ is 
the skin. 
5. The method of claim 1 Wherein the disorder is selected 
from the group consisting of stroke, Parkinsonism, 
concussion, aneurysm, ventricular hemorrhage and associ 
ated vasospasm, migraine and other vascular headaches, 
spinal cord trauma, diabetic retinopathy and neuroanesthesia 
adjunct. 
6. The method of claim 1 Wherein the disorder is selected 
from the group consisting of diabetic peripheral neuropathy 
and traumatic nerve damage. 
7. The method of claim 1 Wherein the disorder is selected 
from the group consisting of atherosclerosis, chronic 
obstructive pulmonary disease, pancreatitis, pulmonary 
?brosis due to chemotherapeutic agents, angioplasty, burns, 
ischemic boWel disease, ulcers and bed sores, lupus, ulcer 
ative colitis, organ transplantation, renal hypertension, over 
exertion of skeletal muscle and epistaxis. 
8. The method of claim 1 Wherein the disorder is the result 
of exposure to cytotoxic compounds and radiation selected 
from the group consisting of X-ray, ultraviolet, gamma or 
beta radiation. 
9. The method of claim 8 Wherein the radiation is ultra 
violet radiation. 
10. The method of claim 1 Wherein said compound is 
administered topically. 
11. The method of claim 10 Wherein said compound is 
administered in conjunction With an ointment or cream base 
suitable for topical administration. 
12. The method of claim 1 Wherein said compound is 
administered in conjunction With a pharmaceutically accept 
able carrier. 
13. The method of claim 1 Wherein said compound is 
administered in a pharmaceutically acceptable carrier 
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selected from the group consisting of carriers for intrave 
nous administration, oral adrninistration, adrninistration via 
the respiratory tract, subcutaneous adrninistration, intrarnus 
cular adrninistration, rectal administration and topical 
administration. 
14. The method of claim 1, Wherein Y is a tert-butyl group 
that can be hydroXylated or acetylated. 
15. The method of claim 1, Wherein Y is phenyl. 
16. The method of claim 1, Wherein Y is 
R2 
CH 
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17. The method of claim 1, Wherein X is irnidaZolyl. 
18. The method of claim 1, Wherein X is phenothiaZinyl. 
19. The method of claim 1 Wherein X is 
20. The method of claim 1 Wherein Z is alkyl. 
* * * * * 
